SAN CARLOS, Calif., Sept 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2008 Global Life Sciences Conference in New York at the Grand Hyatt New York Hotel on Tuesday, September 23, 2008 at 10:30 a.m. ET.
The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2008.
About Nektar
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled eight approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
CONTACT:
Jennifer Ruddock
Nektar Therapeutics
1-650-283-6253
jruddock@nektar.com
SOURCE Nektar Therapeutics
http://www.nektar.com
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX